GSK sues Moderna for US patent infringement over COVID, RSV ...
1 day ago · GSK seeks unspecified monetary damages from Moderna. Oct 15 (Reuters) - British drugmaker GlaxoSmithKline (GLAX.NS) sued Moderna (MRNA.O) in U.S. federal court in Delaware on Tuesday, accusing its ...
GSK agrees to settle about 80,000 Zantac lawsuits for up to ...
Oct 9, 2024 · CNN —. GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced ...
GSK Says Potential Blockbuster Helps Treat Common Nasal ...
2 days ago · October 14, 2024 at 3:06AM EDT. The GSK Plc headquarters in London. Photographer: Vivian Wan/Bloomberg (Vivian Wan/Bloomberg) (Bloomberg) -- GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials in a boost for the UK drugmaker’s pipeline.
ViiV Healthcare shows more than 99% effectiveness in ... - GSK
1 day ago · GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today shared the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long ...
Press releases - GSK
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK makes a strong start to 2024 with improving outlook for ...
May 1, 2024 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for Q1 2024; 60p expected for Full Year 2024.
Press releases | GSK US
US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.
GSK set to face jury trials over heartburn drug Zantac
Jun 1, 2024 · GSK and other pharmaceutical groups are set to face jury trials in cases brought by more than 72,000 cancer sufferers who allege a heartburn drug caused their condition, after a judge in Delaware...
GSK readies for pivotal ruling in Zantac cases - Financial Times
Apr 24, 2024 · The federal court in Florida found that plaintiffs’ scientists’ findings were based on “unreliable methodologies”, in effect dismissing almost 2,500 cases in 2022, a decision that GSK said ...
US FDA approves GSK’s AREXVY, the world’s first respiratory ...
May 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
- Some results have been removed